EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Beremagene geperpavec (B-VEC) gene therapy for the treatment of cutaneous wounds in patients with dystrophic epidermolysis bullosa: a critically appraised research paper

Brent J Doolan, John A McGrath iD, Jemima E Mellerio iD

British Journal of Dermatology · 2024

DOI: 10.1093/bjd/ljad433 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Brent J Doolan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Genetic Skin Disease Group, St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, UK. Hauptthemen laut MEDLINE: Epidermolysis Bullosa Dystrophica, Skin Abnormalities, Epidermolysis Bullosa. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dystrophic epidermolysis bullosa (DEB) is a rare inherited blistering skin disease that causes lifelong, slow-to-heal wounds, which predispose patients to chronic inflammation, scarring and an increased risk of developing squamous cell carcinoma. Management is largely supportive with no approved corrective therapies currently available. We critically appraise the phase III clinical trial reported by Guide et al., investigating the topical application of beremagene geperpavec on cutaneous wounds in DEB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epidermolysis Bullosa DystrophicaSkin AbnormalitiesEpidermolysis BullosaHumansSkinGenetic Therapy

Autor:innen und Institutionen

  • Genetic Skin Disease Group, St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, UK.

ORCID-Profile: John A McGrath, Jemima E Mellerio

Zitieren

APA

Doolan, B. J., McGrath, J. A., & Mellerio, J. E. (2024). Beremagene geperpavec (B-VEC) gene therapy for the treatment of cutaneous wounds in patients with dystrophic epidermolysis bullosa: a critically appraised research paper. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad433

Vancouver

Doolan BJ, McGrath JA, Mellerio JE. Beremagene geperpavec (B-VEC) gene therapy for the treatment of cutaneous wounds in patients with dystrophic epidermolysis bullosa: a critically appraised research paper. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljad433

BibTeX
@article{Doolan2024,
  author = {Doolan, Brent J and McGrath, John A and Mellerio, Jemima E},
  title = {Beremagene geperpavec (B-VEC) gene therapy for the treatment of cutaneous wounds in patients with dystrophic epidermolysis bullosa: a critically appraised research paper},
  journal = {British Journal of Dermatology},
  year = {2024},
  doi = {10.1093/bjd/ljad433}
}
Kostenlos starten →